CA2520406A1 - Cxcr4 antagonists and methods of their use - Google Patents

Cxcr4 antagonists and methods of their use Download PDF

Info

Publication number
CA2520406A1
CA2520406A1 CA002520406A CA2520406A CA2520406A1 CA 2520406 A1 CA2520406 A1 CA 2520406A1 CA 002520406 A CA002520406 A CA 002520406A CA 2520406 A CA2520406 A CA 2520406A CA 2520406 A1 CA2520406 A1 CA 2520406A1
Authority
CA
Canada
Prior art keywords
cancer
cxcr4
cell
antagonist
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002520406A
Other languages
English (en)
French (fr)
Inventor
Hyunsuk Shim
Zhongxing Liang
Jay Umbreit
Russell Taichman
Mark Goodmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emory University
University of Michigan System
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2520406A1 publication Critical patent/CA2520406A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CA002520406A 2003-03-27 2004-03-26 Cxcr4 antagonists and methods of their use Abandoned CA2520406A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45821703P 2003-03-27 2003-03-27
US60/458,217 2003-03-27
PCT/US2004/009570 WO2004087068A2 (en) 2003-03-27 2004-03-26 Cxcr4 antagonists and methods of their use

Publications (1)

Publication Number Publication Date
CA2520406A1 true CA2520406A1 (en) 2004-10-14

Family

ID=33131767

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002520406A Abandoned CA2520406A1 (en) 2003-03-27 2004-03-26 Cxcr4 antagonists and methods of their use

Country Status (5)

Country Link
US (1) US20070258893A1 (enExample)
EP (1) EP1608318A4 (enExample)
JP (1) JP2006524242A (enExample)
CA (1) CA2520406A1 (enExample)
WO (1) WO2004087068A2 (enExample)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8795633B2 (en) 2005-09-23 2014-08-05 Purdue Research Foundation Multiphoton in vivo flow cytometry method and device
US8858914B2 (en) 2002-02-07 2014-10-14 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
US8865128B2 (en) 2002-02-07 2014-10-21 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
US8916167B2 (en) 2001-05-02 2014-12-23 Purdue Research Foundation Treatment and diagnosis of macrophage mediated disease
US8961926B2 (en) 2007-05-25 2015-02-24 Purdue Research Foundation Method of imaging localized infections
US9180215B2 (en) 2007-02-07 2015-11-10 Purdue Research Foundation Positron emission tomography imaging method
US9279813B2 (en) 2006-11-03 2016-03-08 Purdue Research Foundation Ex vivo flow cytometry method and device
US9731035B2 (en) 2005-07-05 2017-08-15 Purdue Research Foundation Method of imaging osteoarthritis using a folate conjugate

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2426139B1 (en) 2002-08-27 2014-10-01 Biokine Therapeutics Ltd. CXCR4 antagonist and use thereof
WO2005103721A1 (en) * 2004-04-20 2005-11-03 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with cxc chemokine receptor 4 (cxcr4)
CA2593612A1 (en) 2005-01-07 2006-07-13 Emory University Cxcr4 antagonists for the treatment of hiv infection
WO2006091112A1 (en) * 2005-02-22 2006-08-31 Genesis Reasearch And Development Corporation Limited Compositions for the delivery of rna interference molecules and methods for their use
US8569280B2 (en) 2005-04-25 2013-10-29 Immune Disease Institute Methods for the treatment of multiple myeloma
US7825088B2 (en) * 2005-04-25 2010-11-02 The Cbr Institute For Biomedical Research, Inc. Methods for the treatment of multiple myeloma
DE102005023170A1 (de) * 2005-05-19 2006-11-23 Curevac Gmbh Optimierte Formulierung für mRNA
WO2006126188A2 (en) * 2005-05-25 2006-11-30 Hadasit Medical Research Services And Development Ltd. Cxcr4 antagonists for wound healing and re-epithelialization
CN101365336B (zh) * 2005-08-19 2013-05-29 健赞股份有限公司 增强化疗的方法
PT1961744E (pt) 2005-11-18 2013-05-15 Ono Pharmaceutical Co Composto que contém um grupo básico e sua utilização
EP2397148A3 (en) * 2006-02-02 2012-04-25 Allergan, Inc. Compositions and methods for the treatment of ophthalmic disease
US8628750B2 (en) 2006-02-27 2014-01-14 Technische Universitat Munchen Cancer imaging and treatment
TW200808328A (en) * 2006-06-02 2008-02-16 Alcon Mfg Ltd RNAi-mediated inhibition of stromal cell-derived factor 1-related targets for treatment of neovascularization-related conditions
WO2008008854A2 (en) 2006-07-11 2008-01-17 Emory University Cxcr4 antagonists including diazine and triazine structures for the treatment of medical disorders
CA2673719C (en) 2006-12-21 2018-07-24 Biokine Therapeutics Ltd. T-140 peptide analogs having cxcr4 super-agonist activity for bone marrow recovery
WO2009039966A2 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
JP5690715B2 (ja) 2008-03-28 2015-03-25 アルテイリス・セラピユーテイクス ケモカイン受容体調節因子
AU2009311645C1 (en) 2008-11-04 2014-10-02 Acer Therapeutics Inc. CXCR4 receptor compounds
BRPI1009663A2 (pt) 2009-06-14 2016-10-11 Biokine Therapeutics Ltd "método para elevação dos níveis plaquetários em um indivíduo com essa necessidade, método de inibição de hemorragia em um indivíduo que a necessite e composição farmacêutica"
WO2011094389A2 (en) * 2010-01-27 2011-08-04 Emory University Cxcr4 antagonists for imaging of cancer and inflammatory disorders
WO2011106703A2 (en) 2010-02-26 2011-09-01 Anchor Therapeutics, Inc. Cxcr4 receptor compounds
CN103108641B (zh) * 2010-09-09 2016-01-13 诺松制药股份公司 Sdf-1结合性核酸及其在癌症治疗中的用途
EP2663320A1 (en) 2011-01-10 2013-11-20 Biokine Therapeutics Ltd. Peptides and compositions for the treatment of neuroectodermal derived tumors and retinoblastoma
EP2476441A1 (en) 2011-01-13 2012-07-18 Universitat Autònoma De Barcelona Methods and reagents for efficient and targeted delivery of therapeutic molecules to CXCR4 cells
EP2771484A1 (en) 2011-10-28 2014-09-03 Galderma Research & Development New leukocyte infiltrate markers for rosacea and uses thereof
US9439942B2 (en) 2012-04-24 2016-09-13 Biokine Therapeutics Ltd. Peptides and use thereof in the treatment of large cell lung cancer
CA2906314A1 (en) 2013-03-24 2014-10-02 Biolinerx Ltd. Methods of treating myeloid leukemia
ES2811804T3 (es) 2013-10-31 2021-03-15 Biokine Therapeutics Ltd Un inhibidor peptídico de CXCR4 para su uso en el tratamiento de la leucemia mieloide aguda con una mutación de FLT3
WO2015114638A2 (en) 2014-02-03 2015-08-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method of eliminating stem cells
KR101700946B1 (ko) * 2014-11-11 2017-02-02 연세대학교 산학협력단 Ｃｘｃｒ４ 길항제를 포함하는 피부 색소침착의 예방 또는 개선용 조성물
PL3277284T3 (pl) * 2015-04-02 2021-03-08 Proximagen, Llc Nowe terapie nowotworu
CN111375066B (zh) * 2015-07-16 2023-04-25 百欧肯治疗有限公司 治疗癌症的组合物及方法
WO2017011517A1 (en) 2015-07-16 2017-01-19 Emory University Bis-amines, compositions, and uses related to cxcr4 inhibition
WO2017023999A1 (en) 2015-08-03 2017-02-09 Emory University Methylsulfonamide derivatives and uses related thereto
MX2018010125A (es) 2016-02-23 2019-03-28 Biolinerx Ltd Procedimientos de tratamiento de leucemia mieloide aguda.
US20210338767A1 (en) 2018-09-25 2021-11-04 Biolinerx Ltd. Methods of selecting treatment for cxcr4-associated cancer
CN110590744B (zh) * 2019-07-03 2021-11-02 河南省人民医院 一种靶向趋化因子受体cxcr4的小分子类pet显像剂

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000009152A1 (en) * 1998-08-14 2000-02-24 The University Of British Columbia Therapeutic chemokine receptor antagonists
EP2426139B1 (en) * 2002-08-27 2014-10-01 Biokine Therapeutics Ltd. CXCR4 antagonist and use thereof

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8916167B2 (en) 2001-05-02 2014-12-23 Purdue Research Foundation Treatment and diagnosis of macrophage mediated disease
US8858914B2 (en) 2002-02-07 2014-10-14 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
US8865128B2 (en) 2002-02-07 2014-10-21 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
US9731035B2 (en) 2005-07-05 2017-08-15 Purdue Research Foundation Method of imaging osteoarthritis using a folate conjugate
US8795633B2 (en) 2005-09-23 2014-08-05 Purdue Research Foundation Multiphoton in vivo flow cytometry method and device
US9279813B2 (en) 2006-11-03 2016-03-08 Purdue Research Foundation Ex vivo flow cytometry method and device
US9180215B2 (en) 2007-02-07 2015-11-10 Purdue Research Foundation Positron emission tomography imaging method
US8961926B2 (en) 2007-05-25 2015-02-24 Purdue Research Foundation Method of imaging localized infections

Also Published As

Publication number Publication date
JP2006524242A (ja) 2006-10-26
WO2004087068A2 (en) 2004-10-14
WO2004087068A3 (en) 2006-02-02
US20070258893A1 (en) 2007-11-08
EP1608318A4 (en) 2009-07-29
EP1608318A2 (en) 2005-12-28

Similar Documents

Publication Publication Date Title
CA2520406A1 (en) Cxcr4 antagonists and methods of their use
KR102473113B1 (ko) 암 치료를 위한 병용 요법
KR20180100599A (ko) 종양 치료용 항-cd20 조합물
CN105008394B (zh) 治疗结肠直肠癌的方法
KR20180101428A (ko) 종양 치료용 항-her2 조합물
JP7678032B2 (ja) がん療法において使用するためのデオキシシチジン誘導体又はデオキシウリジン誘導体
AU2017321322A1 (en) Compositions and methods for treatment of prostate cancer
US8008354B2 (en) Death receptor sensitizing compounds and methods of use therefor
CN115605232A (zh) 用于治疗b-细胞淋巴瘤的联合疗法和生物标志物
US20080206287A1 (en) Use of cyclosporin A to sensitize resistant cancer cells to death receptor ligands
US20190133998A1 (en) Treatment of tumors with inhibitors of cxcl12 signaling and subtherapeutic amounts of chemotherapeutic agents
US20090041751A1 (en) Sepsis Prevention Through Adenosine Receptor Modulation
US20250295686A1 (en) Combination decitabine and mps1 inhibitor therapy to prime cancer immunogenicity
JP2019511544A (ja) アジア人患者におけるレスミノスタットの医薬用途
Rossetti Caratterizzazione funzionale e molecolare di inibitori farmacologici ad attività anti-istone-deacetilasica, in modelli in vitro ed in vivo di Rabdomiosarcoma
HK40091434B (en) Deoxy- cytidine derivatives for use in cancer therapies
HK40091434A (en) Deoxy- cytidine derivatives for use in cancer therapies
BR122024025392A2 (pt) Uso de um composto, kit e composição farmacêutica
BR122024025393A2 (pt) Uso de um composto, kit e composição farmacêutica
against CXCR Inhibition of Breast Cancer Metastasis by Selective Synthetic

Legal Events

Date Code Title Description
FZDE Discontinued